Sequence information
DRAVP ID DRAVPc047
Name Metenkefalin
Sequence
Molecular Formula C27H35N5O7S
Condition/Disease COVID-19
Group Phase Ⅲ clinical trial
Type Peptide
Description Metenkefalin is a synthetic form of the naturally occurring, endogenous opioid peptide, metenkephalin, and agonist of the zeta- and delta-opioid receptor and, to a lesser extent the mu-opioid receptor, with potential analgesic, neuromodulatory, immunomodulatory, anti-inflammatory, antinociceptive/analgesic, antidepressant, and gastrointestinal (GI) motility modulating activities. It is an investigational endogenous opioid being studied for the treatment of COVID-19. Metenkefalin, along with tridecactide, are under investigation as an immunomodulatory therapy for moderate to severe COVID-19.
Active sequence/Structure
External Links
DrugBank Accession Number DB12668
Pubchem ID 443363
CHEMBL ID CHEMBL13786
UNII 9JEZ9OD3AS
CAS 58569-55-4
Reference Not Available
ClinicalTrails Information
| NCT Number | Study Title | Condition/Disease | Status | Phase | Sponsor |
|---|---|---|---|---|---|
| NCT04374032 | Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 Infection | COVID-19 Infection | Completed | Phase 2, 3 | Bosnalijek D.D |
